Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pexiganan acetate

H M Lamb1, L R Wiseman

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 8, 1999
PubMed
Summary
This summary is machine-generated.

Pexiganan acetate, a synthetic peptide, shows broad-spectrum antibacterial activity and is well-tolerated. Clinical trials in diabetic foot ulcers demonstrated comparable efficacy to ofloxacin, with good patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Antimicrobial Peptides
  • Synthetic Antibacterials
  • Wound Infection Treatment

Background:

  • Pexiganan acetate (MSI-78) is a synthetic cationic peptide analogue of the host defense peptide magainin 2.
  • It is designed to disrupt bacterial cell membrane and cell wall permeability.
  • Demonstrates broad-spectrum in vitro activity against Gram-positive and Gram-negative bacteria, including anaerobes.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of topical pexiganan acetate in treating infected diabetic foot ulcers.
  • To compare pexiganan acetate with oral ofloxacin in a Phase III clinical trial setting.

Main Methods:

  • Two multicenter, randomized, double-blind Phase III trials were conducted.
  • Participants were diabetic patients with infected foot ulcers.

Related Experiment Videos

  • Treatment arms included topical pexiganan acetate 1% and oral ofloxacin 800 mg/day.

    • Main Results:

    • Both pexiganan acetate and ofloxacin achieved clinical cure or improvement in approximately 90% of patients.
    • Pathogen eradication rates at end of therapy were 66% for pexiganan acetate and 82% for ofloxacin.
    • No evidence of Staphylococcus aureus resistance developed after in vitro passage.
    • Limited data suggest pexiganan acetate is well tolerated.

    Conclusions:

    • Topical pexiganan acetate demonstrates comparable clinical efficacy to oral ofloxacin for infected diabetic foot ulcers.
    • While pathogen eradication was lower than ofloxacin, pexiganan acetate shows promise as a well-tolerated topical antibacterial agent.
    • Further investigation into its role in wound infection management is warranted.